p Image-guided thermal ablation (IGTA) therapy (eg, cryotherapy, microwave, radiofrequency) may be an option for select patients. 影像引导下热消融治疗原则（NSCL-D）.
rr 生物标志物分析原则（NSCL-H）.
vv 晚期或转移性疾病的生物标志物指导治疗原则（NSCL-J）
ww For PS 0–4.
aaa If there is a good response to current therapy, it is reasonable to continue therapy.
bbb Beware of flare phenomenon in subset of patients who discontinue TKI. If disease flare occurs, restart TKI.
ccc Clinical trials have included up to 3 to 5 progressing sites.
eee Definitive local therapy of CNS disease can include asymptomatic lesions at risk for symptomatic progression based on factors including site, location, and edema.
iii Plasma or tissue-based testing via MGPT should be considered at progression for genomic resistance mechanisms. If plasma-based testing is negative, tissue-based testing
with rebiopsy material is strongly recommended. Practitioners may want to consider scheduling the biopsy concurrently with plasma testing referral.
ppp Entrectinib, repotrectinib, or taletrectinib may be better for patients with brain metastases.
qqq Repotrectinib or taletrectinib is an option for resistant mutations, such as ROS1 G2032R. NCCN-NSCLC-2026V6 NCCN非小细胞肺癌指南导航
